Taspoglutide

What is Taspoglutide?#

Taspoglutide (developmental codes R1583, BIM51077) was a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist co-developed by Roche and Ipsen for the treatment of type 2 diabetes mellitus. It was a 30-amino-acid peptide analog of human GLP-1(7-36 amide) with 93% sequence homology to the native hormone, featuring two alpha-aminoisobutyric acid (Aib) substitutions that conferred resistance to DPP-4 degradation.

Taspoglutide was formulated as a zinc-based slow-release subcutaneous depot, enabling once-weekly administration. It advanced through multiple phase 3 clinical trials (the T-emerge program) but development was halted in September 2010 due to severe gastrointestinal side effects and systemic hypersensitivity reactions.

Mechanism of Action#

As a GLP-1 receptor agonist, taspoglutide activated the same receptor pathways as endogenous GLP-1:

• Glucose-dependent insulin secretion: Stimulated pancreatic beta-cell insulin release in response to elevated blood glucose
• Glucagon suppression: Inhibited inappropriate glucagon secretion from alpha-cells
• Gastric emptying delay: Slowed gastric emptying to reduce postprandial glucose excursions
• Appetite reduction: Central GLP-1 receptor activation in the hypothalamus reduced hunger and food intake

Taspoglutide was considered fully potent at the GLP-1 receptor, equivalent to native GLP-1, with the Aib substitutions providing enzymatic resistance without compromising receptor binding affinity.

Research Overview#

The T-emerge clinical trial program consisted of multiple phase 3 trials evaluating taspoglutide in patients with type 2 diabetes. The program demonstrated robust glycemic efficacy, with taspoglutide consistently reducing HbA1c by 1.0-1.3% across studies, superior to exenatide twice daily and sitagliptin.

However, the safety profile proved unacceptable. Nausea occurred in 53-59% of patients, vomiting in 33-37%, injection-site reactions were frequent and sometimes severe, and systemic allergic reactions were reported. Anti-taspoglutide antibodies were detected in 49% of patients. These tolerability issues resulted in high discontinuation rates and prompted Roche to terminate the program.

Important Considerations#

• Development was halted by Roche in September 2010 and the compound was returned to Ipsen
• Never received regulatory approval from any agency
• The high immunogenicity rate (49% antibody formation) was a critical barrier
• Superior efficacy could not overcome the safety/tolerability limitations
• Development failure contributed to increased focus on non-immunogenic GLP-1 analogs by competing companies

Key Research Findings#

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 Trial, published in Diabetes Care (Nauck MA et al., 2013; PMID: 23139373):

• The study demonstrated anti taspoglutide antibodies detected in of 49% of patients

Related Reading#

• Taspoglutide research studies and evidence
• Taspoglutide dosing protocols
• Taspoglutide side effects profile
• Semaglutide research guide
• Liraglutide research guide